ConductScience.org, home

Paper39600110

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.

Colombo G and 7 others. ESC Heart Fail, 2025. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. Papers, record 39600110. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39600110

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.
PubMed
Journal
ESC Heart Fail
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
4.86, provisional
iCite
Revised in PubMed
2025-05-17
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Colombo GGiada
2Biering-Sorensen TTor
3Ferreira JPJoao P
4Lombardi CMCarlo Mario
5Bonelli AAndrea
6Garascia AAndrea
7Metra MMarco
8Inciardi RMRiccardo M

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Heart FailureMajor topic
Ventricular RemodelingMajor topic
Stroke VolumeMajor topic
Humans
Mineralocorticoid Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists
Adrenergic beta-Antagonists

Source PubMed

Download CSV of topics

References141

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133404637Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.JAMA Cardiol2021https://conductscience.org/library/papers/33404637PubMed
231707802Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.Circ Heart Fail2019https://conductscience.org/library/papers/31707802PubMed
333129742Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.JACC Cardiovasc Imaging2021https://conductscience.org/library/papers/33129742PubMed
432558989Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.Eur J Heart Fail2020https://conductscience.org/library/papers/32558989PubMed
533766629Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.Pharmacol Res2021https://conductscience.org/library/papers/33766629PubMed
615949473Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.Cardiovasc Res2005https://conductscience.org/library/papers/15949473PubMed
735334137Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail2022https://conductscience.org/library/papers/35334137PubMed
832415802The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.Diabetes Metab Res Rev2020https://conductscience.org/library/papers/32415802PubMed
939600110Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.ESC Heart Fail2025https://conductscience.org/library/papers/39600110PubMed
1015201244Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.Heart2004https://conductscience.org/library/papers/15201244PubMed
1130586756Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.Circulation2019https://conductscience.org/library/papers/30586756PubMed
1236183276Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.Circulation2022https://conductscience.org/library/papers/36183276PubMed
1331768479Atrial Myopathy.JACC Basic Transl Sci2019https://conductscience.org/library/papers/31768479PubMed
1429806165Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.Eur J Heart Fail2018https://conductscience.org/library/papers/29806165PubMed
1522157723Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.Circ Heart Fail2012https://conductscience.org/library/papers/22157723PubMed
168941106Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation1996https://conductscience.org/library/papers/8941106PubMed
1733669786Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.Int J Mol Sci2021https://conductscience.org/library/papers/33669786PubMed
187963115Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy.J Am Coll Cardiol1994https://conductscience.org/library/papers/7963115PubMed
1933189632Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.JACC Heart Fail2021https://conductscience.org/library/papers/33189632PubMed
2016141258Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.Eur Heart J2005https://conductscience.org/library/papers/16141258PubMed

See all 141 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42985589Exploration of the Pathogenesis and Treatment of Heart Failure.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42985589PubMed
42888505Prognostic impact of moderate secondary mitral regurgitation after optimized medical therapy in heart failure.ESC Heart Fail2026https://conductscience.org/library/papers/42888505PubMed
42781099Disulfidptosis in heart failure: an emerging mechanism awaiting exploration.Front Cardiovasc Med2026https://conductscience.org/library/papers/42781099PubMed
42679352Dapagliflozin effects on right ventricular function, pulmonary pressure and coupling: a propensity score analysis from the RIVED-HF.ESC Heart Fail2026https://conductscience.org/library/papers/42679352PubMed
42315195Cardioprotective role of antihypertensive treatment in chemotherapy-induced cardiotoxicity: umbrella review of meta-analyses of randomised controlled trials.Open Heart2026https://conductscience.org/library/papers/42315195PubMed
42283978Probing Early Myocardial Remodeling in Response to a High-Fat Diet in Mice by Evaluation of Extracellular Volume Fraction Using 4D Retrospectively Gated Micro-CT Imaging.Mol Imaging Biol2026https://conductscience.org/library/papers/42283978PubMed
42161423Cardiac MRI in cardiac dystrophinopathy: recommendations on imaging.Open Heart2026https://conductscience.org/library/papers/42161423PubMed
41995966Targeting the Apelin-APJ Axis: A Promising Strategy to Mitigate Anthracycline-Induced Cardiotoxicity.Cardiovasc Toxicol2026https://conductscience.org/library/papers/41995966PubMed
41329532
Effects of Isovolumic Loading Elicited Either by 3-Branch or by 4-Branch Spring Expander on the Degree of Cardiac Atrophy of the Failing Heart in Rats After Heterotopic Heart Transplantation: No Evidence for Sex-Linked Differences.
Physiol Res2025https://conductscience.org/library/papers/41329532PubMed
41303740SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era.Medicina (Kaunas)2025https://conductscience.org/library/papers/41303740PubMed
41155138Cardioprotective Mechanisms of Beta-Blockers in Myocardial Ischemia and Reperfusion: From Molecular Targets to Clinical Implications.Int J Mol Sci2025https://conductscience.org/library/papers/41155138PubMed
41089789New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity.Rev Cardiovasc Med2025https://conductscience.org/library/papers/41089789PubMed
40841934Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database.BMC Cancer2025https://conductscience.org/library/papers/40841934PubMed
40672521Regulatory Effects of Zhenxin Formula in Treating Doxorubicin-Induced Heart Failure: Network Pharmacology and Animal Experimental Verification.Drug Des Devel Ther2025https://conductscience.org/library/papers/40672521PubMed
40629225Gut microbiota's role in heart failure.Heart Fail Rev2025https://conductscience.org/library/papers/40629225PubMed
40142759Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice.J Clin Med2025https://conductscience.org/library/papers/40142759PubMed
39600110Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.ESC Heart Fail2025https://conductscience.org/library/papers/39600110PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39600110

GET https://conductscience.org/api/papers/v1/39600110/references?page=2